83
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials

, , &
Pages 3899-3907 | Published online: 25 Nov 2016

References

  • KesslerRCBerglundPDemlerOThe epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)JAMA2003289233095310512813115
  • KulkarniSKDhirACurrent investigational drugs for major depressionExpert Opin Investig Drugs2009186767788
  • AshtonAKJamersonBDWeinsteinLWWagonerCAntidepressant-related adverse effects impacting treatment compliance: results of a patient surveyCurr Ther Res Clin Exp20056629610624672116
  • GeddesJRCarneySMDaviesCRelapse prevention with antidepressant drug treatment in depressive disorders: a systematic reviewLancet2003361935865366112606176
  • FavaMRushAJAlpertJEDifference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D reportAm J Psychiatry2008165334235118172020
  • DawsonLAWatsonJMVilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disordersCNS Neurosci Ther200915210711719499624
  • CoplanJDGopinathSAbdallahCGBerryBRA neurobiological hypothesis of treatment-resistant depression – mechanisms for selective serotonin reuptake inhibitor non-efficacyFront Behav Neurosci2014818924904340
  • PortellaMJde Diego-AdelinoJBallesterosJCan we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depressionJ Clin Psychiatry201172796296921034693
  • KehneJHBartoszykGDGreinerHEIn vitro characterization of vilazodone as a dual-acting serotonin reuptake receptor and 5-HT1A receptor partial agonistPoster presented at: 65th Annual Meeting of the Society of Biological Psychiatry Meeting2010
  • RickelsKAthanasiouMReedCVilazodone, a novel, dual-acting antidepressant: current status, future promise and potential for individualized treatment of depressionPersonali Med20096216224
  • ThaseMEChenDEdwardsJRuthAEfficacy of vilazodone on anxiety symptoms in patients with major depressive disorderInt Clin Psychopharmacol201429635135624978955
  • RickelsKAthanasiouMRobinsonDSGibertiniMWhalenHReedCREvidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trialJ Clin Psychiatry200970332633319284933
  • KhanACutlerAJKajdaszDKA randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorderJ Clin Psychiatry201172444144721527122
  • CroftHAPomaraNGommollCChenDNunezRMathewsMEfficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trialJ Clin Psychiatry20147511e1291e129825470094
  • MathewsMGommollCChenDNunezRKhanAEfficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trialInt Clin Psychopharmacol2015302677425500685
  • LiberatiAAltmanDGTetzlaffJThe PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaborationBMJ2009339b270019622552
  • ShiLPuJXuLMalaguitJZhangJChenSThe efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population – an updated meta-analysisBMC Neurol201414125125527141
  • KennedySHAndersenHFLamRWEfficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysisJ Psychiatry Neurosci200631212213116575428
  • SzegediAJansenWTvan WilligenburgAPvan der MeulenEStassenHHThaseMEEarly improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patientsJ Clin Psychiatry200970334435319254516
  • StorosumJGElferinkAJvan ZwietenBJvan den BrinkWHuyserJNatural course and placebo response in short-term, placebo-controlled studies in major depression: a meta-analysis of published and non-published studiesPharmacopsychiatry2004371323614750046
  • PapakostasGIPerlisRHScaliaMJPetersenTJFavaMA meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorderJ Clin Psychopharmacol2006261566016415707
  • RaoSZisookSAnxious depression: clinical features and treatmentCurr Psychiatry Rep200911642943619909663
  • ClaytonPJGroveWMCoryellWKellerMHirschfeldRFawcettJFollow-up and family study of anxious depressionAm J Psychiatry199114811151215171928465
  • FlintAJRifatSLTwo-year outcome of elderly patients with anxious depressionPsychiatry Res199766123319061801
  • RobinsonDSKajdaszDKGallipoliSWhalenHWamilAReedCRA 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorderJ Clin Psychopharmacol201131564364621869687
  • WardenDRushAJTrivediMHFavaMWisniewskiSRThe STAR*D Project results: a comprehensive review of findingsCurr Psychiatry Rep20079644945918221624
  • MachadoMIskedjianMRuizIEinarsonTRRemission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trialsCurr Med Res Opin20062291825183716968586
  • Montejo-GonzalezALLlorcaGIzquierdoJASSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patientsJ Sex Marital Ther19972331761949292833
  • AlcantaraAGA possible dopaminergic mechanism in the serotonergic antidepressant-induced sexual dysfunctionsJ Sex Marital Ther199925212512910327381